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A B S T R A C T
Rationale: Epilepsy surgery procedures started in Argentina more than 50 years ago. This is the ﬁrst
comprehensive and systematic survey of epilepsy surgery long-term outcome from our country.
Methods: A descriptive cohort study was conducted between 1998 and 2008 for drug-resistant epilepsy
surgery with a minimum of 12 months follow-up (n = 110). In 84 cases (76.36%) resective surgery was
performed, and outcome periodically assessed using the Engel score. Patients were stratiﬁed into
groups: 12, 13–36, 37–60 and over than 60 months of follow-up. Video-EEG with and without
intracranial electrode implants, intraoperative electrocorticograms, Wada tests, pathology reports, use
of antiepileptic drugs (AEDs), and surgical complication rates were evaluated.
Results: Surgical techniques included: 69 lobectomies (62.7%), 15 lesionectomies (13.6%), 6 calloso-
tomies (5.4%), 6 multiple subpial transection (5.4%), 11 vagus nerve stimulations (10%), 3
hemispherectomies (2.7%). Male: female ratio: 1/1.44. Mean age at time of surgery: 26.2 years. Mean
duration of epilepsy: 14 years. Age at seizure onset: 11.5 years. Mean follow-up: 46 months. Pathology
ﬁndings: mesial temporal sclerosis 32 (35.1%); dual pathology 17 (18.7%); cortical dysplasia 15 (16.4%);
non-speciﬁc inﬂammatory changes 11 (12.1%); tumors 7 (7.7%); other 6 (6.8%). Engel scores at 12
months follow-up: 72.6% (61) class I, 16.6% (14) class II and 15.5% (13) class III–IV; 13–36 months after
surgery: 68.1% of cases were class I, 15.9% class II and 15.5% class III–IV. After 37–60 months, 74% class I,
14% class II, 14% class III–IV. Over 60 months (n = 45) 78% class I, 13.5% class II and 8.1% class III–IV.
Conclusion: Conducting a successful epilepsy surgery program in a developing country is challenging.
These results should encourage specialists in these countries. Long-term outcome results comparable to
centres in developed countries can be achieved.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Epilepsy surgery procedures started in Argentina in 1957, in
both public and private institutions .1 So far, this is the ﬁrst
comprehensive and systematic review of epilepsy surgery
outcome from our country since our program began in 1998.
The incidence of epilepsy in developed countries is currently
estimated to be 24–53 patients/100,000 inhabitants, and preva-
lence of active epilepsy between 4 and 8/1000 inhabitants.2 In
Buenos Aires, where epidemiological surveys were performed
between 1991 and 2007, prevalence of epilepsy is estimated in 6.2/
1000.3–5 Eighty percent of patients suffering from the disease
worldwide live in developing countries,6–8 and few papers exist in
the international literature on these procedures and their long-
term outcome in emerging economies. Epilepsy surgery has a long* Corresponding author. Tel.: +54 11 57773474; fax: +54 11 57773475.
E-mail address: cdigiano@ﬂeni.org.ar (C. D’Giano).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.02.002history,1 and is a recognized and accepted treatment for patients
with refractory epilepsy.9,2 Published evidence suggests results are
good, and signiﬁcantly improve patient quality of life, outweighing
risks inherent to the procedure itself.2,9,10 Epilepsy surgery now
affords an excellent opportunity to suppress seizure activity.
Modern techniques used to evaluate surgical results must
assess not only seizure control, but also patient psychosocial
adaptation and quality of life. One universally accepted post-
operative monitoring method often used for long term follow up is
the Engel score; a quantitative scale based on comparing the
number of seizures and/or auras before and after surgery.11
2. Objectives
The aim of this study was to evaluate clinical outcome in
patients with epilepsy refractory to drug treatment, operated on at
our centre between 1998 and 2008 using different surgical
techniques, as well as potential inﬂuence of aetiology on results.vier Ltd. All rights reserved.
Table 1
Engel’s classiﬁcation of postoperative outcome.
Class I: Free of disabling seizures
A: Completely seizure free since surgery
B: Nondisabling simple partial seizures only since surgery
C: Some disabling seizures after surgery, but free of disabling seizures
for at least 2 years
D: Generalized convulsions with AED discontinuation only
Class II: Rare disabling seizures (‘almost seizure free’)
A: Initially free of disabling seizures but has rare seizures now
B: Rare disabling seizures since surgery
C: More than rare disabling seizures since surgery,
but rare seizures for the last 2 years
D: Nocturnal seizures only
Class III: Worthwhile improvement
A: Worthwhile seizure reduction
B: Prolonged seizure-free intervals amounting to greater than half the
followed-up period, but not <2 years
Class IV: No worthwhile improvement
A: Signiﬁcant seizure reduction
B: No appreciable change
C: Seizures worse
[()TD$FIG]
Fig. 1. Resective surgery neuropathology (n = 84).
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A descriptive retrospective cohort study using information from
refractory epilepsy and epilepsy surgery databases in our program
was conducted, byanalysingall patients operatedbetween1998and
2008 for drug-resistant epilepsy. One hundred and ﬁfty cases were
operated on, only cases with a minimum of 12 months follow-up
were included in the study (n = 110). In 84 cases (76.36%) resective
surgery (was performed, and outcome periodically assessed using
the Engel score (Table 1). Engel’s score was systematically assessed
by neurologists/epileptologists or neurosurgeons in follow up visits.
When patients were not available for personal interview personally,
Engel scores were obtained via telephone interview.
Patients were stratiﬁed into groups (Table 2) according to
follow-up duration as follows: 12 months, 13–36 months, 37–60
months and over than 60 months.
Patients were grouped according procedure, namely: lobecto-
my, lesionectomy and corticectomy with and without multiple
subpial transections.
A standard epilepsy MRI protocol was used to study all patients
(GE 1.5 T GE Sigma Excite 1.5 T): sagital T1 sequences (5 mm slice
thickness), coronal FLAIR (5 mm), T2 (3 mm), axial T1, T2 and T2*
(5 mm), sequences of 3D T1 sequences and diffusion of 1.6 mm
slice thickness.
Use of Video-EEGmonitoring prior to surgery with and without
intracranial electrode implants was also evaluated, as well as
intraoperative electrocorticograms (ECoG) and Wada tests.Table 2
Patient clinical characteristics.
Characteristic Number
Gender (%)
Female 65
Male 45
Age at epilepsy onset (years)
Mean 11.5
Range 1–52
Duration of epilepsy (years)
Mean 14
Range 1–50
Age at surgery (years)
Mean 26.2
Range 2–59
Follow up (months)
Mean 46
Range 12–126Pathology reports, number and dose of antiepileptic drugs
(AEDs) before and after surgery, immediate and long term
mortality and surgical complication rates were also analyzed.
Most of the patients received both pre and post-surgical
neuropsychiatric and neurocognitive evaluations but the results
were not analysed in this survey.
4. Results
Surgical techniques performed included: 69 lobectomies
(62.7%), 15 lesionectomies (13.6%), 6 callosotomies (5.4%), 6
multiple subpial transection (5.4%), 11 vagus nerve stimulations
(10%) and 3 hemispherectomies (2.7%).
AEDs were discontinued in 19 patients (17.3%), number of
different AEDs decreased in 22 cases (20%), and drug dose was
reduced in twelve patients (10.9%).
Mean follow-up in this group of patients was 46 months (range
12–126), with a male: female ratio of 1:1.44 (59.1% were females).
Mean age at time of surgery was 26.2  8 years (range 2–59), and
mean duration of epilepsy 14 years. Age at seizure onset was 11.5  6
years. (Table 1).
In 91 patients (83%), pathology reports were obtained and
ﬁndings included: mesial temporal sclerosis 32 (35.1%); dual
pathology 17 (18.7%); cortical dysplasia 15 (16.4%) (Taylor type
40%); nonspeciﬁc inﬂammatory changes 11 (12.1%); tumors 7
(7.7%): ganglioglioma (3), oligodendroglioma (2), pilocytic astro-
cytoma (1), and low grade oligodendroastrocytoma (1); others 6
(6.8%): cavernomas (3), normal (3). Pathology examinationwas not
performed in 19 cases (17%) (Two hemispherectomies, six
callosotomies and eleven vagal nerve stimulations) (Fig. 1).
All patients were evaluated by Video-EEG monitoring. Intra-
cranial electrodes were implanted in 32 cases (29.1%), intra-
operative ECoG was registered in 34 patients (30.9%) and Wada
test conducted in 42 (38.2%).[()TD$FIG]Fig. 2. Favourable resective surgery outcome (Engel 1–2) for all patients at 12 and
>60 months. CD: cortical dysplasia; MTS: mesial temporal sclerosis; NS:
nonspeciﬁc; DP: dual pathology.
[()TD$FIG]
Fig. 3. (A) Favourable (Engel 1–2) and unfavourable (Engel 3–4) resective surgery
outcome at 12, 12–36, 36–60, >60 months. (B) Resective surgery outcome at 12,
12–36, 36–60 and >60 months.
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indicated 71.4% (60) of patients were class I, 15.5% (13) class II and
13.1% (11) class III and IV; 13–36months after surgery (n = 67), we
found 70.1% of cases were class I, 16.4% class II and 13.5% class III–
IV.
Between 37 and 60 months of postoperative follow-up (50
patients), 72% of patients were class I, 14% were class II, while 14%
were class III and IV; and over 60months (n = 45) 71.1% of patients
were class I, 13.3% class II and 15.5% class III–IV. (Fig. 2).
Depending on the aetiology we found: mesial temporal
sclerosis (MTS) was the most common diagnosis, observed in
38% (n = 32) of the total series. Twenty ﬁve of patients (78.1%) were
class I at 1 year follow-up; 70% remained class 1 between 12 and 35
months; 69% between 36 and 60 months, and ﬁnally, in patients
followed over 60months (17 patients) we observed 77% continued
in this class (Fig. 3).
Cortical dysplasia accounted for 17.8% (n = 15), six of which
were ‘‘Taylor type’’. In this subgroup, 11 patients (73.3%)were class
I after 12 months follow-up, 2 patients (13.3%) class II and one
patient class IV (6.6%). At 12–36months follow-up 9 patients (82%)
class I and 2 patients (18%) class II. Four patientswere lost to follow
up after 1 year.
Dual pathology accounted for 20.2% (n = 17). Eleven patients
(64.7%) were class I after a year of follow-up, 3 patients (17.6%)
were class II and 3 patients (17.6%) class III. At 12 to 36 months
follow-up, 9 patients (64.3%) were class I, 3 (21.4%) and 2 (14.2%)
class III. At 60 months 6 patients were class I, 2 (22.2%) class II and
one (11.1%) class III. More than 60 months, 3 patients (60%) class I
and 2 (40%) class II (Fig. 2).
With respect to immediate and long term complications of the
procedure: none were observed in 97 cases (88.2%); two patients
suffered cranial nerve paresis with full recovery; subdural
collections or hematomas responding to medical treatment were
present in 2 cases, and transient motor paresis in 7 patients.
Infection occurred in one patient and cerebral oedema also in one
patient.
Two patients died during follow up, one committing suicide 10
years after surgery, and one from colon cancer 31 months after
surgery.
5. Discussion
Based on follow up ﬁndings and a review of the literature,
patients were classiﬁed as presenting (a) excellent results: when
free of seizures (Engel class I); (b) good results: if without seizures,
or suffering acute isolated seizures only (Engel class I and II); and
(c) only mild changes: when no improvement or only moderate
change was observed (class III and IV). Good outcome was
observed in 89% of patients undergoing resective surgery regard-less of aetiology or type of procedure, 72% of these showing
excellent results at 1 year of follow-up.
5.1. Long-term outcome
Few published reports have addressed the outcome of epilepsy
surgery after 5 years and even fewer have been conducted in
developing or newly industrialized countries. Argentina is
centralized around its capital city Buenos Aires, people from all
over the country come to our centre seeking a comprehensive
epilepsy program, making long-term outcome information collec-
tion difﬁcult. Some few years ago, Cohen-Gadol et al. 12 pointed out
that the reason patients lose or maintain contact with referral
centres may be closely related to outcome status a bias which
increased if patients had to travel long distances for their visits.
Another important issue is that, as we used Engel’s score only for
resective surgeries and not for palliative ones, this may explain the
high rates of excellent outcome results observed in this review. The
group of patients followed for more than 60 months (n = 45)
showed excellent outcome in 76.3% of cases.
A recently published meta-analysis 13 comparing long-term
seizure control after temporal lobe surgery tomedical treatment in
patients with refractory temporal lobe epilepsy, found 44% of
patients were seizure-free, vs. only 12% of those not operated.
Although seizure control effectiveness has shown a trend to
decrease as time after surgery increases (‘‘running-down’’ phe-
nomenon),14–16 no evidence of this was observed in our series.
5.2. Types of procedure
Resective procedures achieved best results (70% excellent
performance), while palliative procedures showed much lower
success rates.
Temporal lobectomies: standard anterior temporal lobectomy
(ATL), spencer type anteromedial resection plus amigdalohippo-
campectomy proved to generate the best results (76% excellent
and 92% favourable outcome), in agreement with published
data.17,18
In 26 palliative surgery cases: 14 patients (53.8%) persistedwith
similar seizure rates, 11 patients (42.3%) showed signiﬁcant
decrease in frequency, and one patient (3.8%) remained seizure
free after over 36 months follow up.19,20
5.3. Aetiologies
In this series, patients with MTS showed the best response to
surgical treatment, with 78.1% presenting excellent outcome after
1 year, and 77% showing stability over time after 60months follow
up.
Cortical dysplasias showed excellent results in 78.6% of cases in
the ﬁrst year, and dual pathology in 64.5%. All seven patients with
brain tumors had excellent outcomes 1 year after surgery.
Extratemporal resections have been generally less successful than
temporal lobe resections. Recent studies report up to 57.5% of
patients operated with neocortical epilepsy as seizure free after 2
years.21 In our experience, 50% of extratemporal surgeries achieve
Engel class I scores 2 years after surgery.
5.4. Antiepileptic drug requirements
The impact of surgical procedures on AE requirements
contributed signiﬁcantly to overall quality of life. While individual
decisions on whether to reduce or withdraw AEDs were left up to
the specialist, 19 patients (17.3%) were able to discontinue them
entirely, 22 patients (20%) reduced the number of drugs taken, and
in 12 cases (10%) dose were reduced, so that a total of 47.3%
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surgery. It is common for patients with difﬁcult to control or
refractory epilepsy to voice their dissatisfaction with chronic need
for medication, often complaining of adverse effects, high drug
costs and difﬁculties complying with drug schedules. A meta-
analysis recently published by Schmidt showed that likelihood of
interrupting AEDs was 4 times greater in surgically treated
patients.13 This fact seems of particular importance given that
discontinuation or reduction of AEDs implies better psychosocial
adaptation and signiﬁcant cost reduction, both for patients and for
health-care providers.
5.5. Morbimortality
Current surgical treatments for epilepsy are safe.22 Eighty eight
percent of all cases in this series were completed without
complications, a rate similar to that described in other similar
studies.10,23 With respect to transient motor paresis, 5 patients
underwent extratemporal resections associated with MST and in 2
cases temporal resections were performed. In a metaanalisis
published by the Subcommittee of the American Academy of
Neurology in association with the American Epilepsy Society and
the American Association of Neurological Surgeons, 16 out of 556
patients (3%) presented transient motor paresis as complication.2
6. Conclusion
Advances in diagnostic techniques and knowledge of underly-
ing pathophysiology have increased both safety and efﬁcacy of
surgical procedures, thus increasing the number of candidates for
epilepsy surgery. Most patients are potentially eligible for non-
invasive methods, and up to 60–80% remain seizure-free after
surgery. However, we believe conducting a successful epilepsy
surgery program in a newly industrialized country is challenging,
both at the technology level, as well as that of well-trained human
resources. As time has elapsed, we have treated cases of increasing
complexity. Early patients in the series were mostly adults
subjected to resective temporal lobe surgery. More recently,
refractory non-lesional focal epilepsy cases have been operated
with encouraging results, although the number is too small to
allow statistical analysis.
A neuro-pathology department is another important issue in a
comprehensive epilepsy program. In our experience, surgical
revision has enabled us to diagnose and classify cortical dysplasias
that had originally gone undetected.
These results should encourage specialists in emerging econo-
mies to study this population, and to train specialized staff and
acquire appropriate technology, as they indicate that results
comparable to those of centres in developed countries can be
achieved. Currently, we believe that early surgery represents the
best opportunity available to patients with refractory epilepsy for
adequate psychosocial rehabilitation and quality of life improve-
ment.
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